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Intrahepatic Human Islet Transplantation at the University of 
Pittsburgh: Results in 25 Consecutive Cases 
P.B. Carroll, C. Ricordi, H.R. Rilo, P. Fontes, R. Khan, A.G. Tzakis, R. Shapiro, J.J. Fung, and T.E. Starzl 
I N PATIENTS with type I diabetes. insulin production by pancreatic islets declines until severnl years after 
onset, and the majority have no demonstrable endogenous 
insulin secretion due to relentless autoimmune destruction 
of insulin-producing B cells. Before 1990, the lack of any 
successful islet cell transplants in humans was frustrating. 
With new developments in the techniques used to isolate 
and purify islets from the human pancreas, short and 
prolonged insulin independence has been reported follow-
ing human islet transplantation in man. We report herein 
our initial experience in human islet allo- and autotrans-
plantation in 25 patients. 
METHODS 
Twenty-five intrahepatic islet grafts were performed in 24 patients 
between January 10. 1990 and April I. 1992. 
Group 1 (Cluster-Islet Recipients) 
Ten patients, aged 8 to 58 years, underwent combined liver islet 
allotransplantation following upper-abdominal exenteration for 
tumors requiring radical surgery that included total pancreatec-
tomy. partial gastrectomy, splenectomy, Iymphnode dissection. 
and liver transplantation. Detailed information on nine of these 
patients has been reported previously. 1.2 Immunosuppression was 
with FK 506 that began with IV doses of 0.075 mglkg every 12 
hours followed by 0.15 mglkg BID when patients were taking oral 
feedings. The dose was adjusted on clinical grounds and by 
monitoring plasma levels. 
Group 2 (Liver-Islet Recipients) 
Three patients With type I diabetes and absent C-peptide to either 
glucagon or Sustacal underwent combined liver and islet trans-
plantation for the indication of cirrhosis. One patient with a 
positive crossmatch died in the first 24 hours following the 
transplant due to hyperacute liver rejection and is not included in 
the data analysis. Immunosuppression in this group was also with 
FK 506 that was administered at a dose of 0.1 mg IV as a 
continuous infusion over 24 hours. In addition. these patients 
received a lOOO-mg bolus of methylprednisolone during the oper-
ation. followed by a maintenance dose of 20 mg IV prednisolone 
until conversion to oral medications. 
Group 3 (Islet Autograft Recipients) 
Two patients underwent a near total pancreatectomy for the 
indication of severe recurrent pancreatitis with pain. One patient 
had pancreatitis due to lupus and the other due to alcoholic 
pancreatic disease. No immunosuppression was used in this 
group. 
Group 4 (Kidney-Islet Recipients) 
Nine patients underwent 10 kidney-islet grafts (one retransplant) 
for indications of end-stage renal disease due to type I diabetes. 
One patient died on the fifth postoperative day of aspiration 
pneumonia. and the data on this patient are not included for 
analysis. Immunosuppression in this group was with FK 506 given 
as in group 2. Following the intraoperative IV bolus of 1000 mg of 
methylprednisolone. a decreasing prednisone dose from 200 to 20 
mgld was given. The last three patients also received 200 mg 
ImuranJd with a tapering of mediations based on clinical criteria. 
Islet Preparation and Administration 
The human islets were obtained from pancreata that were har-
vested from multiorgan donors. 3.4 The human islets were obtained 
by a modification~ of the automated method for human isolation_ 5 
Metabolic Testing 
Group I patients were followed with an intraoperative I-mg 
glucagon stimulation test following the pancreatectomy that con-
firmed absent endogenous insulin secretion. Serial IV glucose 
tolerance tests (lVGm (0.5 glkg) have been followed in this 
group. Groups 2 and 4 underwent screening IV glucagon or oral 
Sustacal (6 cal/kg) followed by postoperative assessment of func-
tion by serial oral Sustacal challenges. Group 3 patients under-
went intraoperative sampling followed by postoperative IVGTIs 
as described above. 
RESULTS 
In group 1, six of ten (60%) patients achieved insulin 
independence for prolonged periods of time (29, 14.22,9, 
10, and 13 months). Of these patients, only 2 had onset of 
hyperglycemia requiring insulin at 10 and 22 months. 
Recurrence of tumor has been a major problem in this 
group and occurred in 5 patients. Three patients are 
currently alive and back to full activities. Six of 10 patients 
had at least one episode of liver rejection documented by 
biopsy. One patient is still insulin independent at 29 
months with HbA1c: 4.8 (nl: 3.9 to 5.9). This patient did not 
have any episodes of allograft rejection of liver or islets. Of 
interest in this patient with the longest graft survival in our 
series was the increase in mean pre- and postprandial 
glucose determinations that occurred at 17 months. This 
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was accompanied by a rise in HbA,c to 7.4%. No inter-
vention was made and glycemic control nonnalized spon-
taneously. In group 2, no patients were insulin-free. Both 
patients had at least one liver rejection episode. One 
patient died of hepatitis B and sepsis 6 months after the 
procedure; the other patient has a stimulated C-peptide 
level >2.0 pmoVmL and a normal glycosylated hemoglo-
bin on 18 U (0.38 U/kg) of insulin daily. In group 3, two of 
two patients are insulin-free at 7 and 17 months after islet 
autograft procedures and both have normal HbAlc values, 
normal glucose values, and normal IV glucose values. In 
group 4, zero of ten patients are insulin-free, although five 
of ten patients continue to have significant C-peptide 
production for up to 24 months following transplantation. 
All ten patients have had kidney rejection episodes in this 
group. Analysis of basal and stimulated C-peptide values 
show cluster> liver> autograft> kidney groups. 
DISCUSSION 
Several cases of intrahepatic human islet allografts have 
been reported with transient6 or prolonged 1.7 .8 insulin 
independence; however, insulin independence occurs in 
the few rather than the many patients who have undergone 
islet transplantation. Our data in cluster patients along 
with the data from other groups in type I diabetes confirm 
that islet cell transplantation is feasible in man. If there are 
no rejection episodes, one donor is enough in many 
patients to allow for insulin independence. What explains 
the excellent results in cluster patients compared to type I 
diabetic patients with liver or kidney transplantation? 
Differences in islet isolation and/or purification techniques 
cannot explain the inferior results in the combined kidney-
islet and liver-islet groups, since the patients received 
islets using the same separation and purification procedure 
by the same islet group. The number of islet equivalents 
was higher in the kidney and liver-islet groups compared 
with those transplanted in ~e cluster and autograft groups 
which did much better clinically. The transplanted islet 
equivalents/kg was also similar in the groups. Possible 
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explanations for the high success rate in cluster patients 
include: (1) less rejection episodes in this group; (2) the 
protective effect of donor islets transplanted into the donor 
liver; (3) native pancreatectomy in the cluster and au-
tograft groups; (4) less diabetogenic immunosuppressive 
agents used in the cluster group; and (5) the absence of 
pre-existing vasculopathy in patients who do not have 
long-standing diabetes may allow for better islet engraft-
ment. HLA matching was similar in the allograft groups 
and. therefore, cannot explain the observed results. The 
protective effect of donor islets into the donor liver cannot 
entirely explain the results since one patient in the cluster-
islet group received third-party islets and achieved long-
term insulin independence. This was never seen in the 
liver-islet group with the same advantage. 
The major obstacle to applying islet cell transplantation 
to type I diabetes is rejection of islets. The exploration of 
alternative sites. mechanisms to induce tolerance in recip-
ients, and brief pretreatment of islets to reduce immuno-
genicity and not sacrifice yield and barrier devices are 
currently under intense investigation. Application of these 
methods in human transplantation will allow for improved 
results in all groups of patients undergoing islet transplan-
tation. 
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